The largest community of pharma leaders

Roche Selects Veeva Development Cloud Applications

PLEASANTON, Calif.–(BUSINESS WIRE)–Veeva Systems (NYSE: VEEV) today announced that Roche (SWX: ROG) has selected Veeva Development Cloud applications globally to streamline clinical, regulatory, and quality processes. The company is switching to unified applications in Vault Clinical, Vault RIM, and Vault Quality suites to increase efficiency, enhance data quality, and drive compliance throughout the product lifecycle.

“Speeding drug development and product supply are strategic priorities for innovative life sciences companies like Roche,” said Rik Van Mol, vice president of Veeva Development Cloud. “Veeva Development Cloud breaks down system and process silos so life sciences companies can more quickly bring innovative treatments to patients.”

Roche is standardizing on clinical applications Vault eTMF and Vault CTMS, regulatory applications Vault Submissions, Vault Registrations, and Vault Submissions Archive, and quality applications Vault QMS and Vault QualityDocs.

Learn more about Veeva Vault Development Cloud at the upcoming Veeva R&D and Quality Summit, October 13-14, 2020. The virtual event is open to life sciences industry professionals. Register and stay up to date on program details at veeva.com/Summit.

Additional Information

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.

Veeva Systems Inc. owns other registered and unregistered trademarks.

Source

Recent Articles

Reven Pharmaceuticals Reports on the Importance of Micronutrients and Vitamins for COVID-19 in a Prestigious Medical Journal

GOLDEN, Colo.--(BUSINESS WIRE)--Reven Holdings, Inc. (“Reven”), a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment...

Anthony Welters Joins Gilead Sciences’ Board of Directors

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Anthony Welters has been appointed to the company’s Board of Directors. Mr. Welters retired...

AVIA Names Linda Finkel as CEO

CHICAGO--(BUSINESS WIRE)--AVIA, the nation’s leading digital transformation partner for healthcare organizations, announced that its board of directors has appointed AVIA President Linda Finkel to...

Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced...

U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury®...